Search Results

Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.

• Authors : Park S; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Korea University, Sejong, South Korea.; Park SH

Subjects: Biological Products*/Biological Products*/Biological Products*/adverse effects ; Omalizumab*; Alopecia/Alopecia/Alopecia/chemically induced

• Source: PloS one [PLoS One] 2022 Jul 27; Vol. 17 (7), pp. e0270906. Date of Electronic Publication: 2022 Jul 27 (Print Publication: 2022).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

Record details

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.

• Authors : Zafari Z; Institute for Heart and Lung Health (IHLH), Faculty of Medicine, University of British Columbia, Vancouver, Canada.; Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Institute, University of British Columbia, Vancouver, Canada.

Subjects: Cost-Benefit Analysis*; Adrenal Cortex Hormones/Adrenal Cortex Hormones/Adrenal Cortex Hormones/*economics ; Adrenergic beta-Agonists/Adrenergic beta-Agonists/Adrenergic beta-Agonists/*economics

• Source: PloS one [PLoS One] 2016 Jan 11; Vol. 11 (1), pp. e0146003. Date of Electronic Publication: 2016 Jan 11 (Print Publication: 2016).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

Record details

The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.

• Authors : Bhutani M; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.; Yang WH

Subjects: Anti-Asthmatic Agents/Anti-Asthmatic Agents/Anti-Asthmatic Agents/*therapeutic use ; Asthma/Asthma/Asthma/*drug therapy ; Omalizumab/Omalizumab/Omalizumab/*therapeutic use

• Source: PloS one [PLoS One] 2017 Aug 31; Vol. 12 (8), pp. e0183869. Date of Electronic Publication: 2017 Aug 31 (Print Publication: 2017).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

Record details

Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab.

• Authors : Roth M; Pulmonary Cell Research, Department Biomedicine, University Basel, Basel, Switzerland; Department Internal Medicine, Pneumology, University Hospital Basel, Basel, Switzerland.

Subjects: Airway Remodeling/Airway Remodeling/Airway Remodeling/*drug effects ; Anti-Asthmatic Agents/Anti-Asthmatic Agents/Anti-Asthmatic Agents/*pharmacology ; Antibodies, Anti-Idiotypic/Antibodies, Anti-Idiotypic/Antibodies, Anti-Idiotypic/*pharmacology

• Source: PloS one [PLoS One] 2015 Sep 02; Vol. 10 (9), pp. e0136549. Date of Electronic Publication: 2015 Sep 02 (Print Publication: 2015).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

Record details

A pilot study of omalizumab in eosinophilic esophagitis.

• Authors : Loizou D; Section on Immunopathogenesis, Food Allergy and Eosinophilic Disorders Program, O&O ALPAN, LLC, Fairfax, VA, United States of America; Amerimmune, Fairfax, VA, United States of America.

Subjects: Anti-Allergic Agents/Anti-Allergic Agents/Anti-Allergic Agents/*administration & dosage ; Eosinophilic Esophagitis/Eosinophilic Esophagitis/Eosinophilic Esophagitis/*drug therapy ; Omalizumab/Omalizumab/Omalizumab/*administration & dosage

• Source: PloS one [PLoS One] 2015 Mar 19; Vol. 10 (3), pp. e0113483. Date of Electronic Publication: 2015 Mar 19 (Print Publication: 2015).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection

Record details

Risk calculator of the clinical response to antihistamines in chronic urticaria: Development and internal validation

• Authors : Sánchez, Jorge; Jaimes, Fabian; García, Elizabeth

• Source: PLoS ONE. February 23, 2024, Vol. 19 Issue 2, e0295791

Record details

Total and specific immunoglobulin E in induced sputum in allergic and non-allergic asthma

• Authors : Crespo-Lessmann, Astrid; Curto, Elena; Mateus, Eder

• Source: PLoS ONE. January 29, 2020, Vol. 15 Issue 1, e0228045

Record details

Gender bias in clinical trials of biological agents for severe asthma: A systematic review.

• Authors : Ciudad-Gutiérrez, Pablo; Fernández-Rubio, Beatriz; Guisado-Gil, Ana Belén

Subjects: SEX discrimination; ASTHMA; SEX factors in disease

• Source: PLoS ONE; 9/23/2021, Vol. 16 Issue 9, p1-16, 16p

Record details

Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study.

• Authors : Lexchin, Joel

• Source: PLoS ONE; 8/1/2024, Vol. 19 Issue 8, p1-10, 10p

Record details

Biologic excipients: Importance of clinical awareness of inactive ingredients.

• Authors : Ionova, Yelena; Wilson, Leslie

Subjects: MANNITOL; POLYSORBATE 80; EXCIPIENTS

• Source: PLoS ONE; 6/25/2020, Vol. 15 Issue 6, p1-13, 13p

Record details